Alcon has acquired the Valeda photobiomodulation devise, using low-level light to help stimulate mitochondrial activity in the cells of the retina, marking a pivotal expansion into non-invasive therapies for early and intermediate dry AMD. #DryAMD

Rallybio is exiting its Recursion/Exscientia partnership on REV102, to refocus on its C5 inhibitor, RLYB116. Will the once-weekly subcutaneously delivered C5 inhibitor sufficiently down regulate systemic complement? #C5inhibitor #Biotech #RareDisease

First patient dosed with PulseSight's non viral vectorised therapy to overexpress transferrin to treat GA in AMD. How well this elctro-transfection technique acts as a delivery method for non-viral gene therapies? #AMD #GA #genetherapy

Interesting study describing the potential use of a C3d-antibody to hone therapeutic delivery to the kidney's of aHUS patients. A number of advantages over systemic targeting of complement for an organ-specific disease. #aHUS #CR1 #complement

4DMT puts everything on the line for its bicistronic approach delivering aflibercept and siRNA against VEGF-C. Does this include pausing its 4D-175 asset delivering shortened FH in GA? #wetAMD #CNV #aflibercept #AAV

Cool study investigating the role of FHR-1 in AMD - with comparisons to murine FHR1 homologue too. Appears to have subtly different localisation profile compared to FHR-2, -4, and -5 as seen in other studies, but its there! #AMD #FHR #ophthalmology

EU okays extended treatment interval for Bayer, Regeneron's higher-dose Eylea This will move the goalposts for assets whose USP is less frequent dosing. How much better are they going to have to be now? Once a year? #wetAMD #antiVEGF #eylea.

This study highlights how subtle ECM glycan changes can unmask innate immune vulnerabilities—offering new clues for AMD pathogenesis and potential therapeutic angles. #VisionResearch #ECM #FH.

The loss of sialic acids could impair FH binding, tipping the immune balance in the retina. But here's the twist: FH staining remains—likely due to FHL-1, a truncated form that predominates in BrM and doesn't bind sialic acid. #Glycobiology #Immunology.

New insights into AMD: A recent study maps the retinal sialome and finds reduced sialic acid at the Bruch's membrane–choroid interface in AMD eyes—potentially impacting complement regulation via factor H (FH). #AMD #Ophthalmology #ComplementSystem

Despite the layoffs and lab closures at BlueRock, their ocular asset OpCT-001, an investigational iPSC-derived cell therapy, should not be affected. OpCT-001 entered phase I/II trials earlier this year. #celltherapy #ophthalmology #clinicaltrials

Stuart Therapeutics’ dry eye drug ST-100 failed its Phase 3 trial. Despite promising Phase 2 data, the novel collagen-repair eyedrop didn’t meet endpoints. They plan another study—but it’s a tough road in #DryEyeDisease R&D. #Biotech #Ophthalmology

ForSight Robotics raises $125M to bring robotic precision to cataract surgery. ORYOM® platform uses AI + robotics to perform ultra-steady eye surgery—10× more precise than the human hand. #MedTech #AI #SurgicalRobotics #Ophthalmology

🇬🇧 The UK wants to be a top 3 global life sciences economy by 2035. How?.🔬 Supercharge R&D & NHS trials.🏗️ Expand labs + upskill 145K workers.💼 £2.5B Innovation Fund.🌐 Global deals + big pharma hubs. #LifeSciences #Biotech #UKInnovation #ClinicalTrials

New single-cell atlas of dry AMD in macaques reveals early retinal degeneration, impaired Müller glia plasticity & ferroptosis-driven neural loss. Ferroptosis inhibitors show promise in mice. Big step toward dry AMD therapies! #AMD #scRNAseq #Ophthalmology

🧠 New stroke research identifies CFHR4 and MBL2 as key biomarkers for predicting long-term outcomes in Acute Cerebral Infarction. Findings support the role of CHZF Capsule in modulating immune pathways. 🔗 NCT06874140 #Stroke #CFHR4 #MBL2 #NeuroScience

High-res, motion-corrected OCT enables precise tracking of subretinal drusenoid deposits in intermediate AMD. Most remain stable, but some regress, fuse, or newly form—enhancing biomarker analysis. 👁️🔬 #AMD #OCT #Imaging #RetinaResearch #Ophthalmology

This should see a shot in the arm of BioTech in Tübingen - BioNTech now has a brand new GMP manufacturing site for mRNA vaccines. BioNTech buys German mRNA vaccine peer CureVac in $1.2B all-stock deal

New study: Elevated systemic complement factors predict faster progression from intermediate to advanced AMD. Early identification could enable personalized care before vision loss. 🧬👁️ #AMD #Ophthalmology #Biomarkers #EyeHealth #Research

Great to see that investments are still being made in the ophthalmic gene therapy space. I hope this vision niche remains strong despite the problems faced by systemic gene therapy approaches. #ophthalmology #AAV #genetherapy